Abstract: The present application discloses an antibody or antigen-binding fragment thereof that binds specifically to a BAG2 polypeptide or fragment thereof, and a method of treating cancer thereof.

Abstract: The present invention relates to a composition for preventing or treating a bone disease, obesity or an obesity-mediated metabolic disease, cancer, or cancer metastasis, and a method of screening a drug for treating the diseases, which includes an inhibitor of transmembrane 4 L six family member 19 (TM4SF19) expression or activity.

Abstract: The present invention provides an intermediate for synthesizing a TGF-? inhibitor represented by Chemical Formula 1 and an improved method for preparing the TGF-? inhibitor represented by Chemical Formula 1 using the same. The preparation method according to the present invention can not only allow inexpensive and safe reagents to be used, but also simplify the synthesis steps and purification methods to improve the reaction yield, thereby maximizing the production efficiency of the TGF-? inhibitor represented by Chemical Formula 1 to be used usefully for mass production.

Abstract: The present invention relates to a composition for preventing or treating a bone disease, obesity or an obesity-mediated metabolic disease, cancer, or cancer metastasis, and a method of screening a drug for treating the diseases, which includes an inhibitor of transmembrane 4 L six family member 19 (TM4SF19) expression or activity.

Abstract: The present invention provides an intermediate for synthesizing a TGF-? inhibitor represented by Chemical Formula 1 and an improved method for preparing the TGF-? inhibitor represented by Chemical Formula 1 using the same. The preparation method according to the present invention can not only allow inexpensive and safe reagents to be used, but also simplify the synthesis steps and purification methods to improve the reaction yield, thereby maximizing the production efficiency of the TGF-? inhibitor represented by Chemical Formula 1 to be used usefully for mass production.

Abstract: The present invention relates to methods for treating colorectal cancer patients comprising selecting patients who express high level of the TGF-? response signatures and co-administering TGF-? inhibitor with human immunoglobulin. The invention also relates to the method of diagnosing and selecting patients which is likely to benefit from the treatment comprising the determination of the gene expression levels of TGF-? response signature by analyzing histopathologic images of stroma or RNA sequence from the patients.

Abstract: Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.

Abstract: Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.

Abstract: Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.

Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.

Abstract: Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.

Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.

Abstract: Provided are a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method of preventing or treating chronic myeloid leukemia using the same, thereby being effectively applied to the prevention or treatment of chronic myeloid leukemia.

Abstract: Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis.

Abstract: Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis.

Abstract: A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.